Cargando…
Safety and effectiveness of apixaban versus warfarin for acute venous thromboembolism in patients with end‐stage kidney disease: A national cohort study
BACKGROUND: Patients with end‐stage kidney disease (ESKD) are at significantly increased risk for both thrombosis and bleeding relative to those with normal renal function. The optimal therapy of venous thromboembolism (VTE) in patients with ESKD is unknown. OBJECTIVE: To compare the safety and effe...
Autores principales: | Ellenbogen, Michael I., Ardeshirrouhanifard, Shirin, Segal, Jodi B., Streiff, Michael B., Deitelzweig, Steven B., Brotman, Daniel J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804323/ https://www.ncbi.nlm.nih.gov/pubmed/35929542 http://dx.doi.org/10.1002/jhm.12926 |
Ejemplares similares
-
Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease
por: Cohen, Alexander T., et al.
Publicado: (2021) -
Hospital Resource Utilization and Costs Associated With Warfarin Versus
Apixaban Treatment Among Patients Hospitalized for Venous Thromboembolism in the United
States
por: Deitelzweig, Steven, et al.
Publicado: (2018) -
Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity
por: Cohen, Alexander, et al.
Publicado: (2021) -
Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice
por: Weycker, Derek, et al.
Publicado: (2018) -
Effectiveness and safety of apixaban vs warfarin among venous thromboembolism patients at high-risk of bleeding
por: Cohen, Alexander T., et al.
Publicado: (2022)